The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

TAK-653 / Osavampator

C
Animal replicated
Research chemicalAMPA Receptor PAMSmall MoleculeAntidepressant Candidate
RouteNasalGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
NBI-1065845 — Selective AMPA Receptor Positive Allosteric Modulator — Takeda / Neurocrine Biosciences — AMPA Receptor PAM, Small Molecule, Antidepressant Candidate.
Why people use it
Used primarily for cognitive support.
If you only read one thing

TAK-653 (osavampator) is the most pharmacologically rational attempt to extract ketamine's antidepressant benefit without its mechanism liability. Ketamine works but cannot be taken at home, requires clinical supervision, produces dissociation, and has documented abuse potential — all of which limit its utility as a chronic antidepressant. An oral once-daily AMPA PAM that produces the same BDNF and plasticity changes through the downstream receptor without any of the dissociation would be a genuine clinical advance in antidepressant pharmacology. The Phase 2 SAVITRI data (September 2025) showed statistically significant antidepressant effects. The Phase 1 CNS pharmacodynamic data showed no dissociation, no body sway, no subjective drug effects. The compound appears to achieve the hypothesized clean profile. Phase 3 will determine whether the efficacy magnitude is sufficient for regulatory approval in a field where placebo response is notoriously high and clinical trials expensive.

Check interactions →
Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
3human RCTs0human studies2animal2in vitro

Human controlled evidence includes Phase 1 CNS pharmacodynamics plus Phase 2 depression/TRD programs, including SAVITRI; it remains investigational and not FDA-approved.

Evidence reality check
Human evidence
3 human studies
3 randomized; 0 observational.
Preclinical base
4 lab signals
2 animal; 2 in-vitro/mechanistic.
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Cognition & Mood
Properties
✓ Human RCTNot injectable
Evidence
CAnimal replicated
The AMPA PAM Mechanism in One Paragraph
AMPA receptors (GluA1-4 subunits, also called GluR1-4) are ionotropic glutamate receptors that mediate the majority of fast excitatory synaptic transmission in the brain. When glutamate binds, AMPA receptors open an ion channel allowing Na+ and Ca2+ influx, depolarizing the postsynaptic neuron. This excitatory activity, sustained across relevant brain circuits (hippocampus, prefrontal cortex), drives BDNF production and synaptic plasticity — the structural and functional changes in neural circuits that correlate with antidepressant benefit. A positive allosteric modulator (PAM) binds a site separate from the glutamate binding site; it does not activate the receptor alone but amplifies the receptor's response when glutamate naturally binds. TAK-653 is a PAM of GluR1 specifically — increasing synaptic strength without causing the direct overactivation (and potential excitotoxicity) of full agonism.
Phase 2 SAVITRI — The Most Recent Data (September 2025)
Neurocrine Biosciences presented Phase 2 SAVITRI results at Psych Congress 2025 (September 22, 2025): osavampator demonstrated statistically significant and clinically meaningful improvements in depression severity and was well-tolerated in adults with MDD who had inadequate response to antidepressant treatment. Dose-finding study design: n=183 adults aged 18-65; randomized 2:1:1 to placebo, osavampator 1 mg, or osavampator 3 mg; once daily for 8 weeks. The presentation received the 2025 Poster Award at the 38th annual Psych Congress. Primary endpoint: depression severity reduction (likely HAMD-17 or MADRS). Both doses outperformed placebo with statistical significance. Full paper pending peer-reviewed publication.
How It Differs From Ketamine
Ketamine and esketamine (Spravato) produce rapid antidepressant effects via NMDA receptor antagonism — blocking glutamate's ability to activate NMDA receptors, which triggers downstream BDNF and synaptic plasticity changes. The AMPA receptor pathway is actually downstream of ketamine's NMDA blockade — the AMPA receptor upregulation that follows NMDA blockade is thought to mediate part of ketamine's antidepressant effect. TAK-653 addresses this more directly: it enhances AMPA receptor activity without NMDA blockade, potentially capturing the antidepressant downstream pathway without ketamine's dissociative side effects. The Phase 1 CNS pharmacodynamic study (Translational Psychiatry 2022) confirmed: no body sway, no subjective drug effects (no 'high', no dissociation) at both 0.5mg and 6mg in healthy volunteers. The absence of dissociation removes a major barrier to outpatient use and eliminates the abuse potential concern.
Development Status May 2026
Takeda developed TAK-653 through Phase 2a (NCT03312894, TRD) and Phase 2 SAVITRI (NCT05203341, MDD adjunct). Neurocrine Biosciences received exclusive global license (ex-Japan) from Takeda. Neurocrine presented SAVITRI Phase 2 results September 2025 (statistically significant; well-tolerated). Phase 3 planning for MDD adjunct indication anticipated. Community access: research chemical from several vendors; oral small molecule; 1-3 mg/day based on Phase 2 doses; not FDA-approved.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
J-147
C
Same class · Small Molecule

The Drug That Reversed Brain Aging in Mice. Discovered by Phenotypic Screen. Target Unknown for 7 Years. ATP Synthase: The Unexpected Bridge Between Alzheimer's and Aging. BDNF Induction. AMPK/mTOR via a Completely Novel Entry Point. Phase 1 Human Safety Trial Completed (NCT03838185). The Compound That Is Structurally Related to Curcumin But Pharmacologically Nothing Like It.

Naltrexone / LDN
C
Same class · Small Molecule

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

Selegiline
C
Same class · Small Molecule

The Drug That Extended Rat Lifespan in 1988 and Still Fascinates the Longevity Community. Irreversible MAO-B Inhibitor. Dopamine Preservation. BDNF Upregulation. The DATATOP Trial: Symptomatic Effect, Not Neuroprotection — The Distinction That Matters. The Amphetamine Metabolites: L-Enantiomers Only — What That Means Clinically. Low-Dose Community Protocols (1-5 mg Every Few Days). Why High-Dose Loses MAO-B Selectivity and What Happens Then. Selegiline vs Rasagiline. The Cheese Reaction: When It Applies and When It Doesn't.

Check interactions